Role of histone demethylase JMJD1A in the DNA damage response of prostate cancer cells
组蛋白去甲基化酶 JMJD1A 在前列腺癌细胞 DNA 损伤反应中的作用
基本信息
- 批准号:9753739
- 负责人:
- 金额:$ 34.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-10 至 2021-07-31
- 项目状态:已结题
- 来源:
- 关键词:AmericanAndrogen ReceptorAndrogensBiochemicalCastrationCellsDNA DamageDNA MarkersDNA RepairDNA Repair GeneDNA strand breakDNA-dependent protein kinaseDataDefectEP300 geneGene ExpressionGene Expression RegulationGenesGenetic TranscriptionGoalsGrowthHistonesHumanImmunohistochemistryImpairmentIn VitroIonizing radiationLysineMalignant NeoplasmsMalignant neoplasm of prostateModificationMonitorMusNude MiceOutcomePathway interactionsPhenotypePhosphorylationProcessProstateProstate Cancer therapyProstatic NeoplasmsProteinsProto-Oncogene Proteins c-mycQuantitative Reverse Transcriptase PCRRadiation Induced DNA DamageRadiation therapyRadioRadioresistanceReportingRoleStainsTailTestingTissue MicroarrayTissuesTumor TissueUbiquitinationWestern BlottingWorkXRCC2 geneXRCC3 geneXenograft procedureandrogen deprivation therapybasec-myc Geneschemotherapydeprivationdosagegene functiongene repairgenotoxicityhistone demethylasein vivoknock-downmenmutantnew therapeutic targetnoveloutcome forecastoverexpressionprostate cancer cellprostate cancer cell lineprostate cancer progressionprotein degradationprotein functionprotein protein interactionradiation effectrecruitrepairedresearch studyresponsesmall hairpin RNAtargeted treatmenttherapeutic biomarkertumortumor growthtumor xenografttumorigenesisubiquitin ligaseubiquitin-protein ligase
项目摘要
ABSTRACT
PCa is the most common malignancy in American men. Therapies for advanced PCa include androgen
deprivation therapy (ADT), chemotherapy and radiotherapy, all of which can induce the DNA damage. Thus
the DNA damage response and expression of DNA repair genes are key factors in determining outcome of
genotoxic therapies for PCa. We have identified a pathway in which the histone demethylase JMJD1A
undergoes a non-canonical ubiquitination by the E3 ubiquitin ligase HUWE1, which in turn enhances JMJD1A
co-activation of androgen receptor and c-Myc transcription factors. Here, we will test the hypothesis that the
non-canonical ubiquitination of JMJD1A regulates expression of DNA repair genes through AR and c-Myc, and
promotes growth and survival of PCa cells under ionizing radiation (IR) and androgen deprivation conditions.
Aim one will assess JMJD1A mechanisms in regulating AR and c-Myc transcriptional activity. Aim two will
investigate JMJD1A function in DNA damage responses after IR and androgen deprivation in vitro. Aim three
will evaluate JMJD1A function in the response of xenografted prostate tumors to castration and IR. Finally, in
Aim four, we will investigate the aberrant expression of factors comprising HUWE1/JMJD1A/DNA repair gene
pathway in a human PCa tissue microarray (TMA). Our proposed studies should define a new pathway,
including JMJDJ1A and its targets and regulators, that governs PCa responses to ADT and radiotherapy. If
successful, this work may identify new therapeutic targets or markers for anti-PCa therapy.
摘要
前列腺癌是美国男性最常见的恶性肿瘤。晚期前列腺癌的治疗方法包括雄激素
剥夺疗法(ADT)、化疗和放射治疗都会引起DNA损伤。因此,
DNA损伤反应和DNA修复基因的表达是决定预后的关键因素
前列腺癌的基因毒性疗法。我们已经确定了组蛋白去甲基酶JMJD1A的一个途径
通过E3泛素连接酶HUWE1进行非典型的泛素化,进而增强JMJD1A
雄激素受体和c-Myc转录因子的共同激活。在这里,我们将检验这一假设
JMJD1A的非规范泛素化通过AR和c-Myc调节DNA修复基因的表达,并
促进PCa细胞在电离辐射(IR)和雄激素剥夺条件下的生长和存活。
目的研究JMJD1A调节AR和c-Myc转录活性的机制。目标二意志
研究JMJD1A在体外IR和去雄激素后DNA损伤反应中的作用。目标三
将评估JMJD1A在异种移植前列腺肿瘤对去势和IR的反应中的作用。最后,在
目的研究HUWE1/JMJD1A/DNA修复基因相关因子的异常表达
人前列腺癌组织微阵列(TMA)中的途径。我们提议的研究应该定义一条新的途径,
包括JMJDJ1A及其靶点和调节器,管理对ADT和放射治疗的PCA反应。如果
如果成功,这项工作可能会为抗前列腺癌治疗确定新的治疗靶点或标记物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jianfei Qi其他文献
Jianfei Qi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jianfei Qi', 18)}}的其他基金
Role of JMJD1A modifications in castration resistance of prostate cancer
JMJD1A 修饰在前列腺癌去势抵抗中的作用
- 批准号:
10413979 - 财政年份:2020
- 资助金额:
$ 34.28万 - 项目类别:
Role of JMJD1A modifications in castration resistance of prostate cancer
JMJD1A 修饰在前列腺癌去势抵抗中的作用
- 批准号:
10631171 - 财政年份:2020
- 资助金额:
$ 34.28万 - 项目类别:
Role of histone demethylase JMJD1A in the DNA damage response of prostate cancer cells
组蛋白去甲基化酶 JMJD1A 在前列腺癌细胞 DNA 损伤反应中的作用
- 批准号:
9330125 - 财政年份:2016
- 资助金额:
$ 34.28万 - 项目类别:
Role of histone demethylase JMJD1A in the DNA damage response of prostate cancer cells
组蛋白去甲基化酶 JMJD1A 在前列腺癌细胞 DNA 损伤反应中的作用
- 批准号:
9980296 - 财政年份:2016
- 资助金额:
$ 34.28万 - 项目类别:
Role of histone demethylase JMJD1A in the DNA damage response of prostate cancer cells
组蛋白去甲基化酶 JMJD1A 在前列腺癌细胞 DNA 损伤反应中的作用
- 批准号:
9153175 - 财政年份:2016
- 资助金额:
$ 34.28万 - 项目类别:
Role of JMJD1A in hypoxia-induced EMT and prostate cancer stem cells
JMJD1A 在缺氧诱导 EMT 和前列腺癌干细胞中的作用
- 批准号:
8733791 - 财政年份:2013
- 资助金额:
$ 34.28万 - 项目类别:
Role of JMJD1A in hypoxia-induced EMT and prostate cancer stem cells
JMJD1A 在缺氧诱导 EMT 和前列腺癌干细胞中的作用
- 批准号:
8737200 - 财政年份:2013
- 资助金额:
$ 34.28万 - 项目类别:
Role of JMJD1A in hypoxia-induced EMT and prostate cancer stem cells
JMJD1A 在缺氧诱导 EMT 和前列腺癌干细胞中的作用
- 批准号:
8903769 - 财政年份:2013
- 资助金额:
$ 34.28万 - 项目类别:
Role of Jmjd1a in hypoxia-induced EMT and prostate cancer stem cells
Jmjd1a 在缺氧诱导 EMT 和前列腺癌干细胞中的作用
- 批准号:
8111892 - 财政年份:2011
- 资助金额:
$ 34.28万 - 项目类别:
Role of Jmjd1a in hypoxia-induced EMT and prostate cancer stem cells
Jmjd1a 在缺氧诱导 EMT 和前列腺癌干细胞中的作用
- 批准号:
8309461 - 财政年份:2011
- 资助金额:
$ 34.28万 - 项目类别:
相似海外基金
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
- 批准号:
DP230103210 - 财政年份:2023
- 资助金额:
$ 34.28万 - 项目类别:
Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 34.28万 - 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
- 批准号:
10650956 - 财政年份:2023
- 资助金额:
$ 34.28万 - 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
- 批准号:
10488954 - 财政年份:2023
- 资助金额:
$ 34.28万 - 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
- 批准号:
10651105 - 财政年份:2023
- 资助金额:
$ 34.28万 - 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
$ 34.28万 - 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
- 批准号:
10544062 - 财政年份:2022
- 资助金额:
$ 34.28万 - 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
- 批准号:
10534943 - 财政年份:2022
- 资助金额:
$ 34.28万 - 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
- 批准号:
10677989 - 财政年份:2022
- 资助金额:
$ 34.28万 - 项目类别: